



AFREZZA® REMS

FDA Required REMS Safety Information

- **Risk of acute bronchospasm in patients with chronic lung disease**
 - Acute Bronchospasm has been observed in patients with asthma and COPD using AFREZZA
- **Contraindicated in patients with chronic lung disease such as asthma or COPD**
- **Need to evaluate all patients for lung disease before starting AFREZZA**
Before initiating AFREZZA, perform
 - a detailed medical history
 - physical examination, and
 - spirometry (FEV1)

June 2014

Important Safety Notice

From PDR on behalf of MannKind Corporation

Re: Recent FDA approval of AFREZZA (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus.

Dear Healthcare Provider:

The FDA has required this safety notice as part of the AFREZZA REMS (Risk Evaluation and Mitigation Strategy) to inform healthcare providers (HCPs) about the following **serious risks of AFREZZA:**

- **Risk of Acute Bronchospasm in Patients with Chronic Lung Disease.**
 - Counsel patients to inform their HCP if they have a history of lung disease
 - Do not use in patients with chronic lung disease
- **Appropriate Patient Selection.** AFREZZA is contraindicated in patients with:
 - Chronic lung disease such as asthma or chronic obstructive pulmonary disease (COPD)

- **Patient Evaluation Before Initiating Therapy.**

- Before initiating, prescribers must perform a detailed medical history, physical examination, and spirometry (FEV₁) in all patients, to identify potential underlying lung disease

A non-promotional factsheet, reviewed by the FDA, with more detailed safety information on these risks, and a link to the Prescribing Information including the BOXED WARNING are available at www.AfrezzaREMS.com.

Indication: AFREZZA (insulin human) Inhalation Powder is a rapid acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.

Important limitations of use:

- Not a substitute for long-acting insulin. In patients with type-1 diabetes, must use with a long-acting insulin
- Not recommended for the treatment of diabetic ketoacidosis
- Not recommended in patients who smoke or have recently stopped smoking

Please visit www.AfrezzaREMS.com for more information.

This letter does not contain the complete safety profiling for AFREZZA. Please see the Prescribing Information and Medication Guide, enclosed.

Reporting Adverse Events

You are encouraged to report negative side effects of prescription drugs to MannKind Corporation at 1-877-323-8505 and/or the FDA www.fda.gov/medwatch, or call 1-800-FDA-1088.

Signature,



Nikhil Amin, M.D.
Vice President, Clinical Development
MannKind Corporation